SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Edward Boghosian who wrote (1684)1/10/2000 6:08:00 PM
From: Edward Boghosian  Respond to of 2173
 
Is todays rise due to the analyst or something more substantive?



To: Edward Boghosian who wrote (1684)1/10/2000 6:33:00 PM
From: Edward Boghosian  Read Replies (2) | Respond to of 2173
 
According to Reuters, the company made an announcement that the drug AC 2993 was helpful in suppressing triglycerides and glucagon during phase 11, type 2 trials. Additional testing will continue later this year. Can I say this is very positive or just positive? Are there other drugs that are potential money makers and now being tested?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News